The Latest Headlines at American Banking and Market News
Enphase Energy (NASDAQ:ENPH) Given New $130.00 Price Target at Truist Financial
Enphase Energy (NASDAQ:ENPH – Free Report) had its price objective decreased by Truist Financial from $145.00 to $130.00 in a research report report published on Tuesday, Benzinga reports. Truist Financial currently has a buy... More of this article »
Doximity (NASDAQ:DOCS) Receives Underweight Rating from Morgan Stanley
Morgan Stanley reissued their underweight rating on shares of Doximity (NASDAQ:DOCS – Free Report) in a research report released on Tuesday, Benzinga reports. The firm currently has a $25.00 price objective on the stock. DOCS... More of this article »
Enlivex Therapeutics (NASDAQ:ENLV) Given “Buy” Rating at HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Enlivex Therapeutics (NASDAQ:ENLV – Free Report) in a report issued on Tuesday, Benzinga reports. HC Wainwright currently has a $7.00 price objective on the stock. Enlivex... More of this article »
Caesars Entertainment (NASDAQ:CZR) Given New $58.00 Price Target at Truist Financial
Caesars Entertainment (NASDAQ:CZR – Free Report) had its price objective decreased by Truist Financial from $62.00 to $58.00 in a report issued on Tuesday morning, Benzinga reports. Truist Financial currently has a buy rating... More of this article »
Crocs (NASDAQ:CROX) Price Target Raised to $124.00 at UBS Group
Crocs (NASDAQ:CROX – Free Report) had its price objective hoisted by UBS Group from $117.00 to $124.00 in a report published on Tuesday, Benzinga reports. They currently have a neutral rating on the textile maker’s stock. Several... More of this article »
Cidara Therapeutics’ (CDTX) Overweight Rating Reaffirmed at Cantor Fitzgerald
Cantor Fitzgerald reiterated their overweight rating on shares of Cidara Therapeutics (NASDAQ:CDTX – Free Report) in a research report sent to investors on Tuesday morning, Benzinga reports. Separately, HC Wainwright reissued... More of this article »
Corcept Therapeutics (NASDAQ:CORT) Receives Buy Rating from HC Wainwright
HC Wainwright restated their buy rating on shares of Corcept Therapeutics (NASDAQ:CORT – Free Report) in a research report sent to investors on Tuesday morning, Benzinga reports. The brokerage currently has a $38.00 target price... More of this article »
Cadence Design Systems (NASDAQ:CDNS) Price Target Lowered to $318.00 at Piper Sandler
Cadence Design Systems (NASDAQ:CDNS – Free Report) had its price target reduced by Piper Sandler from $334.00 to $318.00 in a research note published on Tuesday, Benzinga reports. Piper Sandler currently has a neutral rating... More of this article »
Capital Bancorp (NASDAQ:CBNK) Price Target Cut to $26.00 by Analysts at Hovde Group
Capital Bancorp (NASDAQ:CBNK – Free Report) had its price target decreased by Hovde Group from $27.00 to $26.00 in a research report released on Tuesday, MarketBeat Ratings reports. Hovde Group currently has an outperform rating... More of this article »
Cathay General Bancorp (NASDAQ:CATY) Price Target Lowered to $41.00 at Keefe, Bruyette & Woods
Cathay General Bancorp (NASDAQ:CATY – Free Report) had its target price cut by Keefe, Bruyette & Woods from $46.00 to $41.00 in a research report sent to investors on Tuesday morning, Benzinga reports. They currently have... More of this article »-logo.png?v=20230920074015&w=240&h=220&zc=2){kind=logo}
Maplebear (NASDAQ:CART) Given Hold Rating at Needham & Company LLC
Needham & Company LLC reiterated their hold rating on shares of Maplebear (NASDAQ:CART – Free Report) in a research report report published on Tuesday morning, Benzinga reports. A number of other analysts also recently... More of this article »
BioXcel Therapeutics’ (BTAI) Buy Rating Reaffirmed at HC Wainwright
HC Wainwright restated their buy rating on shares of BioXcel Therapeutics (NASDAQ:BTAI – Free Report) in a research note released on Tuesday morning, Benzinga reports. The brokerage currently has a $10.00 target price on the... More of this article »
Beam Global’s (BEEM) Buy Rating Reaffirmed at Roth Mkm
Roth Mkm restated their buy rating on shares of Beam Global (NASDAQ:BEEM – Free Report) in a research note published on Tuesday morning, Benzinga reports. Roth Mkm currently has a $9.00 price target on the stock. Several other... More of this article »